Literature DB >> 8886606

Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human.

R Bort1, X Ponsoda, E Carrasco, M J Gómez-Lechón, J V Castell.   

Abstract

Aceclofenac ([2-(2',6'-dichlorophenylamino)phenyl]acetoxyacetic acid) is a novel nonsteroidal antiinflammatory drug, the pharmacokinetics and drug metabolism of which show species differences. After oral administration to the rat, circulating aceclofenac rapidly disappears yielding [2-(2',6'-dichlorophenylamino)phenyl]acetic acid (diclofenac), which is then further oxidized to [2-(2',6'-dichloro-4'-hydroxyphenylamino)phenyl[acetic acid (4'-hydroxydiclofenac) and [2-(2',6'-dichloro-4'-hydroxyphenylamino)phenyl]acetic acid (4'-hydroxydiclofenac) and [2-(2',6'-dichlorophenylamino)-5-hydroxyphenyl]acetic acid (5-hydroxydiclofenac). This is a minor route in humans, wherein aceclofenac is hydroxylated to [2-(2',6'-dichloro-4'-hydroxyphenylamino)phenyl]acetoxyacetic acid (4'-hydroxyaceclofenac), which becomes the major metabolite. In the monkey, the conversion of aceclofenac to diclofenac takes place, but to a much lesser extent than in the rat, and the 4'-hydroxylated metabolites from both compounds are found in monkeys' urine. The mechanistic basis for this species-dependent variations seems to be the different stability of the drug toward liver esterases. In the rat, the most efficient aceclofenac-hydrolyzing activity is found in hepatic microsomes (Vmax = 2113 +/- 177 pmol/min/mg protein and KM = 191 +/- 40 microM) and cytosol (Vmax = 479 +/- 37 pmol/min/mg protein and KM = 75 +/- 22 microM). Consequently, incubation of aceclofenac with cultured rat hepatocytes or in the rat in vivo results in a rapid hydrolysis of the drug, followed by oxidative metabolism of the resulting diclofenac, yielding 4'- and 5-hydroxylated derivatives as the major metabolites. In contrast, the aceclofenac ester bond is much more stable toward human hepatic microsomal (Vmax = 27 +/- 10 pmol/min/mg protein and KM = 792 +/- 498 microM) and cytosolic (Vmax = 87 +/- 5 pmol/min/mg protein and KM 218 +/- 30 microM) esterases, and 4'-hydroxyaceclofenac becomes the major metabolite in cultured human hepatocytes, as well as in human urine. The research presented herein also illustrates the suitability of cultured human hepatocytes for predicting aceclofenac metabolism in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886606

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study.

Authors:  Simon C Mastbergen; Nathalie W D Jansen; Johannes W J Bijlsma; Floris P J G Lafeber
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

2.  Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study.

Authors:  Young-Wan Moon; Seung-Baik Kang; Tae-Kyun Kim; Myung-Chul Lee
Journal:  Knee Surg Relat Res       Date:  2014-02-27

3.  Controlled and tuneable drug release from electrospun fibers and a non-invasive approach for cytotoxicity testing.

Authors:  G Piccirillo; D A Carvajal Berrio; A Laurita; A Pepe; B Bochicchio; K Schenke-Layland; S Hinderer
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

4.  Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats.

Authors:  Tae Hwan Kim; Subindra Kazi Thapa; Da Young Lee; Seung Eun Chung; Jun Young Lim; Hyeon Myeong Jeong; Chang Ho Song; Youn-Woong Choi; Sang-Min Cho; Kyu-Yeol Nam; Won-Ho Kang; Soyoung Shin; Beom Soo Shin
Journal:  Pharmaceutics       Date:  2018-09-06       Impact factor: 6.321

5.  NMR-Guided Repositioning of Non-Steroidal Anti-Inflammatory Drugs into Tight Junction Modulators.

Authors:  Takeshi Tenno; Kohki Kataoka; Natsuko Goda; Hidekazu Hiroaki
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.